RT Journal Article
SR Electronic
T1 Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.09.20171132
DO 10.1101/2020.08.09.20171132
A1 Kaiyuan Sun
A1 Wei Wang
A1 Lidong Gao
A1 Yan Wang
A1 Kaiwei Luo
A1 Lingshuang Ren
A1 Zhifei Zhan
A1 Xinghui Chen
A1 Shanlu Zhao
A1 Yiwei Huang
A1 Qianlai Sun
A1 Ziyan Liu
A1 Maria Litvinova
A1 Alessandro Vespignani
A1 Marco Ajelli
A1 Cécile Viboud
A1 Hongjie Yu
YR 2020
UL http://medrxiv.org/content/early/2020/11/19/2020.08.09.20171132.abstract
AB A long-standing question in infectious disease dynamics concerns the role of transmission heterogeneities, driven by demography, behavior and interventions. Based on detailed patient and contact tracing data in Hunan, China we find 80% of secondary infections traced back to 15% of SARS-CoV-2 primary infections, indicating substantial transmission heterogeneities. Transmission risk scales positively with the duration of exposure and the closeness of social interactions and is modulated by demographic and clinical factors. The lockdown period increases transmission risk in the family and households, while isolation and quarantine reduce risks across all types of contacts. The reconstructed infectiousness profile of a typical SARS-CoV-2 patient peaks just before symptom presentation. Modeling indicates SARS-CoV-2 control requires the synergistic efforts of case isolation, contact quarantine, and population-level interventions, owing to the specific transmission kinetics of this virus.One Sentence Summary Public health measures to control SARS-CoV-2 could be designed to block the specific transmission characteristics of the virus.Competing Interest StatementMarco Ajelli has received research funding from Seqirus. Hongjie Yu has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. A.V. reports a past grant from Metabiota Inc. is not related to this work. None of these awards are related to COVID-19. All other authors declare no competing interests.Funding StatementHongjie Yu acknowledges financial support from the National Science Fund for Distinguished Young Scholars (number 81525023) and the National Science and Technology Major Project of China (numbers 2018ZX10201001-010, 2018ZX10713001-007, and 2017ZX10103009-005). Lidong Gao acknowledges financial support from Hunan Provincial Innovative Construction Special Fund: Emergency response to COVID-19 outbreak (No. 2020SK3012). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The collection of specimens, epidemiological and clinical data for SARS-CoV-2 infected individuals was part of a continuing public health investigation of an emerging outbreak, defined by the Protocol on the Prevention and Control of COVID-19 established by the National Health Commission of the People's Republic of China (52). Thus, collection of epidemiological and clinical data was exempt from institutional review board assessment. This study was approved by the Institutional review board from Hunan Provincial Center for Disease Control and Prevention (IRB#2020005). Data were deidentified, and informed consent was waived with appropriate institutional form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original database containing confidential patient information cannot be made public however, we created a synthetic mock database to demonstrate the underlying data structure. All code, mock database, along with de-identified data to reproduce all figures in the main text and supplementary material are publicly available at doi:10.5281/ZENODO.4129864 https://doi.org/10.5281/zenodo.4129863